Seres Therapeutics (MCRB) Files for $100M IPO
Get Alerts MCRB Hot Sheet
Join SI Premium – FREE
Seres Therapeutics, Inc. (Nasdaq: MCRB) filed a registration with the U.S. SEC for an IPO of its Common Stock. The proposed maximum offering price is $100 million. The company plans to list on the Nasdaq Global Market under the ticker, MCRB.
Underwriters are Goldman, Sachs & Co., BofA Merrill Lynch, Leerink Partners, and Canaccord Genuity.
Seres Therapeutics is a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- YY Group Holding (YYGH) Closes $5M IPO
- AZZ, Inc. (AZZ) Announces Proposed 4M Share Offering
- Nanometrics (NANO) Issues Business Update, Reports FY23 Results
Create E-mail Alert Related Categories
IPOsRelated Entities
Canaccord Genuity, IPOSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!